Clinical Trial Update: Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating subretinal Lucentis (ranibizumab) for hemorrhagic age-related macular degeneration has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Retinal Hemorrhage

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Corewell Health East | Conditions: Retinal Hemorrhage, Macular Degeneration | Phase 1 | Status: WITHDRAWN